Summary
The relevance of protein binding, molecular size and lipophilicity to tissue penetration of antimicrobials is discussed, and the clinical relevance of tissue penetration of these agents is assessed.
In order to assess the relevance of any factor on the clinical outcome of a group of infections it is necessary to obtain some form of dose response; i.e. the dose has to be (intentionally or otherwise) titrated down until negative responses are seen. Information on clinical failures tends not to be reported, hence useful data are difficult to obtain.
The relevance of protein binding to the microbiological activity of a drug is important and the use of some highly bound agents in readily assessable diseases is illustrated with a few examples: the poor efficacy of fusidic acid in gonorrhoea, when high failure rates are found with doses of 2g; ceftriaxone in gonorrhoea, at doses (25mg) with which one would expect cures, is associated with significant failures; the failure of cefoperazone in serious illness can be related to the degree of protein binding.
The degree of tissue penetration (protein binding apart) is related to clinical efficacy in urinary tract infections (where ample evidence is available), chest infections (where the data are somewhat fewer but probably convincing) and meningitis where experimental data are firm but clinical information less readily available.
Similar content being viewed by others
References
Barza M, Brusch J, Bergeran MG, Weinstein L. Penetration of antibiotics into fibrin focci in vivo. Journal of Infectious Diseases 129: 73–78, 1974
Barza M, Cuchural G. General principles of antibiotic tissue penetration. Journal of Antimicrobial Chemotherapy 15 (Suppl. A): 59–75, 1985
Barza M, Weinstein L. Pharmacokinetics of the penicillins in man. Clinical Pharmacokinetics 1: 297–308, 1976
Bergan T, Engeset A, Olszewski W, Solberg R. Pharmacokinetics of bacampicillin and bacmecillinam in plasma and peripheral lymph. Lymphology 12: 85–94, 1979
Bolivar R, Fainstein V, Elting L, Bodey GP. Cefoperazone for the treatment of infections in patients with cancer. Reviews of Infectious Diseases 5 (Suppl.): S181–S187, 1983
Chisholm GD, Waterworth PM, Calnan JS, Garrod LP. Concentrations of antibacterial agents in interstitial tissue fluid. British Medical Journal 1: 569–573, 1973
Craig WA, Suh B. Theory and practical impact of binding of antimicrobials to serum proteins and tissue. Scandinavian Journal of Infectious Diseases 14 (Suppl.): 92–99, 1978
Craig WA, Welling PG. Protein binding of antimicrobials: clinical pharmacokinetics and therapeutic implications. Clinical Pharmacokinetics 2: 252–268, 1971
Davis SD. Activity of gentamicin, tobramycin, polymixin B and colistimethate in mouse protection tents with Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy 8: 50–53, 1975
Davis BD, Wood WB. Studies on antibacterial action of sulphonamide drugs. Proceedings of the Society of Experimental Biology and Medicine 51: 283–285, 1942
Decazes JM, Ernst JD, Sande MA. Correlation of in vitro timekill curves and kinetics of bacterial killing in CSF during ceftriaxone therapy of experimental E. coli meningitis. Antimicrobial Agents and Chemotherapy 24: 463–467, 1983
Fisher LS, Chow AW, Yoshikaea TJ, Gaze LB. Cephalothin and cephaloridine therapy for bacterial meningitis. Annals of Internal Medicine 82: 689–693, 1975
Garrod LP, Lambert HP, O’Grady F, et al. In Antibiotics and chemotherapy, 1st ed., p. 427, Churchill Livingstone, London, 1981
Gerding DN, Hall WH. The penetration of antibiotics into peritoneal fluid. Bulletin of the New York Academy of Medicine 51: 1016–1019, 1975
Gerding DN, Kromhout JP, Sullivan JJ, Hall WH. Antibiotic tissue penetration of ascitic fluid in dogs. Antimicrobial Agents and Chemotherapy 10: 850–855, 1976
Gerding DN, Peterson LR, Hughes CE, Bamberger DM. Extravascular antimicrobial distribution in man. In Lorian (Ed.) Antibiotics in Laboratory Medicine, 2nd ed., Williams and Wilkins, Baltimore, 1986
Gold R, Jin E, Levison H, Isles A, Fleming PC. Ceftazidime alone and in combination in patients with cystic fibrosis. Journal of Antimicrobial Chemotherapy 12 (Suppl. A): S331–336, 1983
Guttler F, Tybring L. Interaction of albumin and fusidic acid. British Journal of Pharmacology 43: 151–160, 1971
Howell A, Sutherland R, Rolinson GN. Effect of protein binding on levels of ampicillin and cloxacillin in synovial fluid. Clinical Pharmacology and Therapeutics 13: 72–74, 1972
Jackson GG. Methods for the clinical evaluation of antibiotics in urinary tract infections. Scandinavian Journal of Infectious Diseases 14 (Suppl.): 289–294, 1978
Kaiser AB, McGee ZA. Aminoglycoside therapy of Gram-negative bacillary meningitis. New England Journal of Medicine 293: 1215–1220, 1975
Klempner MS, Styrt B. Clindamycin uptake by human neutrophils. Journal of Infectious Diseases 144: 472–479, 1981
Kucers A, Bennett N. (Eds). Use of antibiotics, 3rd ed., pp. 462–469, Heinemann, London, 1979
Kunin CM. Clinical significance of protein binding of the penicillins. New York Academy of Science 145: 282–290, 1967
Kunin CM, Craig WA, Kornguth M, Monson R. Influence of protein binding on the pharmacologic activity of antibiotics. New York Academy of Science 296: 214–234, 1973
Lorian V. In Rook & Sande (Eds) Effect of antibiotics on bacterial structure in new dimensions in antimicrobial chemotherapy, pp. 37–81, Churchill Livingstone, New York, 1984
Maesen FPV, Beewkes H, Davies BI, Buytendijk HJ, Brombacher PJ, et al. Bacampicillin in acute exacerbations of chronic bronchitis, a dose range study. Journal of Antimicrobial Chemotherapy 2: 279–285, 1976
Maesen FPV, Davies BI, Brouwers J, Salemans T, Wamper MN, et al. Latamoxef (moxalactam) in acute exacerbations of chronic bronchitis. Journal of Antimicrobial Chemotherapy 11: 113–123, 1983
Mandell GL. Interaction of intraleukocytic bacteria and antibiotics. Journal of Clinical Investigation 52: 1673–1679, 1973
May JR, Delves DM. Treatment of chronic bronchitis with ampicillin. Lancet 1: 929–931, 1965
McCabe WR, Jackson GG. Treatment of pyelonephritis: successes and failures related to bacteria, drug and host factors. New England Journal of Medicine 272: 1037–1044, 1965
McCabe WR, Jackson GG, Greble HG. Treatment of chronic pyelonephritis. Archives of Internal Medicine 104: 710–719, 1959
McCrae WM, Raeburn JA, Hanson EJ. Tobramycin therapy of infections due to Pseudomonas aeruginosa in patients with cystic fibrosis. Journal of Infectious Diseases 134 (Suppl.): S191–S193, 1976
McCracken GH. The rate of bacteriologic response to antimicrobial therapy in neonatal meningitis. American Journal of Diseases of Childhood 123: 547–533, 1972
McCracken GH. Pharmacokinetics and bacteriological correlations between antimicrobial therapy of experimental meningitis in rabbits and meningitis in humans: a review. Journal of Antimicrobial Chemotherapy 12 (Suppl. D): 97–108, 1983
McCracken GH, Mize SG, Threlkeld N. Intraventricular gentamicin therapy in Gram-negative bacillary meningitis of infancy. Lancet 1: 787–791, 1980
McCracken GH, Nelson JD, Grim L. Pharmacokinetics and bacteriological efficacy of cefoperazone, cefuroxime, ceftriaxone and moxalactam in experimental Streptococcus pneumoniae and Haemophilus influenzae meningitis. Antimicrobial Agents and Chemotherapy 21: 262–267, 1982
Merrikin DJ, Briant J, Rolinson DN. Effect of protein binding on antibiotic activity in vivo. Journal of Antimicrobial Chemotherapy 11: 233–238, 1983
O’Dell GB. The dissociation of bilirubin from albumin and its clinical implications. Journal of Pediatrics 55: 268–279, 1959
Peterson LR, Gerding DN. Influence of protein binding of antibiotics on serum pharmacokinetics and extravascular penetration: clinically useful concepts. Reviews of Infectious Diseases 2: 340–348, 1980
Peterson LR, Gerding DN, Moody JA, Fasching CE. Comparison of azlocillin, ceftizoxime, cefoxitin and amikacin alone and in combination against Pseudomonas aeruginosa in a neutropenic-site rabbit model. Antimicrobial Agents and Chemotherapy 25: 545–552, 1984a
Peterson LR, Van Etta LL, Fasching GE, Gerding DN. Effect of protein binding on simulated intravascular and extravascular kinetics of cefotaxime in an in vitro model. Antimicrobial Agents and Chemotherapy 25: 58–61, 1984b
Rauws AG, VanKlingeren B. Estimation of antibiotic levels in interstitial fluid from whole tissue levels. Scandinavian Journal of Infectious Diseases 14 (Suppl.): S186–S188, 1978
Reeves DS, Rowe RCG, Snell ME, Thomas ABW. Further studies on the secretion of antibiotics in the prostatic fluid of the dog. In Brumfitt & Asscher (Eds) Urinary tract infection, pp. 197–215, Oxford University Press, London, 1973
Rolinson GN, Sutherland R. The binding of antibiotics to serum protein. British Journal of Pharmacology 25: 638–650, 1965
Ryan DM, Mason U, Harding SM. The penetration of ceftazidime into extravascular fluid. Journal of Antimicrobial Chemotherapy 8 (Suppl. B): 283–288, 1981
Sakata Y, McCracken GH, Thomas ML, Olsen KD. Pharmacokinetics and therapeutic efficacy of imipenem, ceftazidime and ceftriaxone in experimental meningitis due to an ampicillin and chloramphenicol resistant strain of H. influenzae type b. Antimicrobial Agents and Chemotherapy 25: 29–32, 1984
Schreiner A, Helium KB, Digranes A, Bergman I. Transfer of penicillin G and ampicillin into human skin blisters induced by suction. Scandinavian Journal of Infectious Diseases 14 (Suppl.): S233–S237, 1978
Stamey TA, Fair WR, Timothy MM, Millar MA, Mihwa G, et al. Serum versus urinary antimicrobial concentrations in cure of urinary tract infections. New England Journal of Medicine 291: 1159–1163, 1974
Stewart SM, Andersen IME, Jones GR, Calder MA. Amoxycillin levels in sputum, serum and saliva. Thorax 29: 110–114, 1974
Stockel K. Pharmacokinetics of rocephin, a highly active new cephalosporin with an exceptionally long biological half-life. Chemotherapy 1 (Suppl.): S42–S46, 1981
Thomsett R, Schultz S, McDermott W. The relationship of protein binding to the pharmacology and antibacterial activity of penicillins X, G, Dihydro F and K. Journal of Bacteriology 53: 581–595, 1947
Van Etta LL, Kravitz GR, Russ TE, Fasching CE, Gerding DN, et al. Effect of method of administration on extravascular penetration of four antibiotics. Antimicrobial Agents and Chemotherapy 21: 873–880, 1982
Verwey WF, Williams HR. Binding of various penicillins by plasma and peripheral lymph obtained from dogs. Antimicrobial Agents and Chemotherapy 484–491, 1963
Waterman NG, Raff MJ, Scharfenberger L, Barnwell PA. Protein binding and concentrations of cephaloridine and cefazolin in serum and interstitial fluid of dogs. Journal of Infectious Diseases 133: 642–647, 1976
Weinstein L, Diakos GK, Perrin TS. Studies on the relationship of tissue fluid and blood levels of penicillin. Journal of Laboratory and Clinical Medicine 38: 712–719, 1951
Wilkins TD, West SEH. Therapy of anaerobic infections. Infection 11 (Suppl. 2): S105–S109, 1983
Wise R. Protein binding of β-lactams: the effects on activity and pharmacology, particularly tissue penetration, I. Journal of Antimicrobial Chemotherapy 12: 1–18, 1983a
Wise R. Protein binding of β-lactams: the effects on activity and pharmacology, particularly tissue penetration. II. Journal of Antimicrobial Chemotherapy 12: 105–118, 1983b
Wise R, Gillett AP, Cadge B, Durham SR, Baker S. The influence of protein binding upon tissue fluid levels of six β-lactam compounds. Journal of Infectious Diseases 142: 77–82, 1980
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Wise, R. The Clinical Relevance of Protein Binding and Tissue Concentrations in Antimicrobial Therapy. Clin-Pharmacokinet 11, 470–482 (1986). https://doi.org/10.2165/00003088-198611060-00004
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003088-198611060-00004